CalciMedica Inc./$CALC
1D1W1MYTD1Y5YMAX
About CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
- Ticker
- $CALC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 16
- Headquarters
- La Jolla, United States
- Website
- calcimedica.com
CalciMedica Inc. Metrics
BasicAdvanced
$16M
-
-$1.33
1.12
-
Price and volume
Market cap
$16M
Beta
1.12
52-week high
$7.20
52-week low
$0.44
Average daily volume
358K
Financial strength
Current ratio
5.577
Quick ratio
5.334
Long term debt to equity
166.878
Total debt to equity
166.878
Interest coverage (TTM)
-15.16%
Profitability
EBITDA (TTM)
-19.595
Management effectiveness
Return on assets (TTM)
-63.58%
Return on equity (TTM)
-365.70%
Valuation
Price to book
2.59
Price to tangible book (TTM)
2.59
Price to free cash flow (TTM)
-0.388
Free cash flow yield (TTM)
-257.92%
Free cash flow per share (TTM)
-1.198
Growth
Earnings per share change (TTM)
-15.19%
3-year earnings per share growth (CAGR)
-57.07%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.